论文部分内容阅读
目的 评价国产头孢他美酯对临床致病菌的体内抗菌活性。方法 通过抗菌药物对小鼠腹腔感染模型保护的方法，并与对照药头孢克洛进行对比，观察了国产头孢他美酯体内抗菌活性。结果 国产头孢他美酯对本实验中大肠杆菌９７２０１５的ＥＤ５０为１－１８ｍｇ·ｋｇ－１，用克雷伯肺炎杆菌９７４４８的ＥＤ５０为２－９４ｍｇ·ｋｇ－１，均与对照药头孢克洛相当，经统计学处理，无显著性差异；对化脓性链球菌９７１０２的ＥＤ５０为０－２８７ｍｇ·ｋｇ－１，好于对照药头孢克洛，经统计学处理，有极显著差异。结论 国产头孢他美酯具有良好的体内抗菌活性，能明显提高小鼠感染大肠杆菌、克雷伯肺炎杆菌和化脓性链球菌的生存率，提示国产头孢他美酯具有良好的生物利用度。
Objective To evaluate the in vivo antibacterial activity of domestic ceftazidime against clinical pathogenic bacteria. Methods The antimicrobial agents were used to protect mouse model of intraperitoneal infection and compared with the control drug cefaclor. The antibacterial activity of domestic cefetamet was observed. Results domestic ceftazidime in this experiment E. coli 97 2015 ED50 1-18mg · kg-1, with Klebsiella pneumoniae 97 4448 ED50 of 2-94mg · kg-1, were compared with the control drug cephalosporin Clopidogrel, statistically, no significant difference; Streptococcus pyogenes 97 102 ED50 0-287mg · kg-1, better than the control drug cefaclor, the statistical analysis, a very significant difference . Conclusion Domestic cefetamet pivoxil has good antibacterial activity in vivo, can significantly improve the survival rate of mice infected with Escherichia coli, Klebsiella pneumoniae and Streptococcus pyogenes, suggesting that the domestic cefetamet ester has good bioavailability.